The therapeutic utility of cell cycle arrest biomarkers such as uTIMP‐2 and insulin‐like growth factor‐binding protein 7 (IGFBP7) for risk stratification of AKI in CI people was evaluated in a large prospective multicenter trial. Here, IGFBP7 is linked to acute kidney injury.